Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tactile Systems TechnologyFRA:3L3 +1.75%84 3-Year EBITDA Growth Rate is 168.00% as of Jun. 2026, which is 1798% above its 10-year median of 8.85. GuruFocus rates FRA:3L3 with a GF Score™ of 84/100 and a GF Value™ of €16.72 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 688 Medical Devices & Instruments companies, Tactile Systems Technology ranks better than 99.56% on this metric.
During the past 12 months, Tactile Systems Technology's average EBITDA Per Share Growth Rate was 58.40% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 168.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Tactile Systems Technology was 168.00% per year. The lowest was -50.40% per year. And the median was 8.85% per year.
Tactile Systems Technology (FRA:3L3) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Tactile Systems Technology 3-Year EBITDA Growth Rate Related Terms
FRA:3L3 vs CERS, NPCE, SENS: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Tactile Systems Technology's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tactile Systems Technology 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tactile Systems Technology's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Tactile Systems Technology's 3-Year EBITDA Growth Rate falls into.
Tactile Systems Technology 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 168.00% mean?
Tactile Systems Technology (FRA:3L3) has a 3-Year EBITDA Growth Rate of 168.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Tactile Systems Technology and its competitors. This is 1798% above median its historical median of 8.85. According to the industry distribution chart, Tactile Systems Technology ranks #3 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 0.40000000000001%.
Is Tactile Systems Technology's 3-Year EBITDA Growth Rate too high?
Tactile Systems Technology's current 3-Year EBITDA Growth Rate of 168.00% is 1798% above median its 10-year median of 8.85. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. Tactile Systems Technology's value of 168.00% is 1974.1% above this industry median. Based on the distribution chart, Tactile Systems Technology ranks #3 out of 688 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Tactile Systems Technology has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tactile Systems Technology's 3-Year EBITDA Growth Rate compare to CERS and NPCE?
According to the Medical Devices & Instruments industry distribution chart, Tactile Systems Technology ranks #3 out of 688 companies for 3-Year EBITDA Growth Rate. This places Tactile Systems Technology in the top 0% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.10. Tactile Systems Technology's value of 168.00% is 1974.1% above this benchmark. While the company's 10-year median is 8.85 vs. the industry median of 8.10, Tactile Systems Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tactile Systems Technology's current 3-Year EBITDA Growth Rate of 168.00% is 1974.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Tactile Systems Technology and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tactile Systems Technology's current 3-Year EBITDA Growth Rate is 168.00%, which is 1798% above median its own 10-year median of 8.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tactile Systems Technology stock overvalued right now?
Based on GuruFocus' analysis, Tactile Systems Technology (FRA:3L3) is currently considered Modestly Overvalued. The stock's GF Value™ is €16.72, compared to a current price of €19.14 — trading 14.5% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 168.00%, which is 1798% above median its 10-year median of 8.85 and 1974.1% above the Medical Devices & Instruments industry median of 8.10. Tactile Systems Technology's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Tactile Systems Technology (FRA:3L3), the current 3-Year EBITDA Growth Rate is 168.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tactile Systems Technology (FRA:3L3) Overvalued in 2026?
Based on GuruFocus' analysis, Tactile Systems Technology stock appears to be overvalued.
The current stock price of €19.14 is trading 14.5% above its estimated GF Value™ of €16.72.
GuruFocus considers Tactile Systems Technology to be Modestly Overvalued.
Key valuation signals for FRA:3L3:
3-Year EBITDA Growth Rate: 168.00% (1798% above median its 10-year median of 8.85)
GF Value™: €16.72 vs. price of €19.14 (14.5% above fair value)
Industry Position: 1974.1% above the Medical Devices & Instruments median (#3 of 688)
No single metric tells the full story. See the FRA:3L3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system, provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
84GF Score
Get the complete analysis for FRA:3L3
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3L3 has been successfully added to your 
